Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Open Access
- 1 July 1997
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 100 (1) , 58-67
- https://doi.org/10.1172/jci119521
Abstract
The urokinase receptor (uPAR) coordinates plasmin-mediated cell-surface proteolysis and promotes cellular adhesion via a binding site for vitronectin on uPAR. Because vitronectin also binds plasminogen activator inhibitor type 1 (PAI-1), and plasmin cleavage of vitronectin reduces PAI-1 binding, we explored the effects of plasmin and PAI-1 on the interaction between uPAR and vitronectin. PAI-1 blocked cellular binding of and adhesion to vitronectin by over 80% (IC50 approximately 5 nM), promoted detachment of uPAR-bearing cells from vitronectin, and increased cellular migration on vitronectin. Limited cleavage of vitronectin by plasmin also abolished cellular binding and adhesion and induced cellular detachment. A series of peptides surrounding a plasmin cleavage site (arginine 361) near the carboxy-terminal end of vitronectin were synthesized. Two peptides spanning res 364-380 blocked binding of uPAR to vitronectin (IC50 approximately 8-25 microM) identifying this region as an important site of uPAR-vitronectin interaction. These data illuminate a complex regulatory scheme for uPAR-dependent cellular adhesion to vitronectin: Active urokinase promotes adhesion and also subsequent detachment through activation of plasmin or complex formation with PAI-1. Excess PAI-1 may also promote migration by blocking cellular adhesion and/or promoting detachment, possibly accounting in part for the strong correlation between PAI-1 expression and tumor cell metastasis.Keywords
This publication has 58 references indexed in Scilit:
- Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?The Journal of cell biology, 1996
- High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.1993
- Prevention of metastasis by inhibition of the urokinase receptor.Proceedings of the National Academy of Sciences, 1993
- Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.Journal of Clinical Investigation, 1993
- Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasivenessBioEssays, 1993
- Accumulation of Type 1 Plasminogen Activator Inhibitor and Vitronectin at Sites of Cellular Necrosis and InflammationAnnals of the New York Academy of Sciences, 1992
- Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue.Journal of Clinical Pathology, 1988
- Cell-Associated Plasminogen Activation: Regulation and Physiological FunctionsAnnual Review of Cell Biology, 1988
- Novel purification of vitronectin from human plasma by heparin affinity chromatography.Cell Structure and Function, 1988
- The Directed Migration of Eukaryotic CellsAnnual Review of Cell Biology, 1986